Clinical Trial Update: A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019) [Phase 2]

View source ↗

Summary

Phase 2 trial of the MK0777 Gel Extrusion Module for generalized anxiety disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• MK0777 Gel Extrusion Module (GEM)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Generalized Anxiety Disorder | Phase 2 | Status: COMPLETED